Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | -0.97% | -9.73% | +28.63% |
Financials (USD)
Sales 2024 * | 63.79M | Sales 2025 * | 47.16M | Capitalization | 261M |
---|---|---|---|---|---|
Net income 2024 * | -150M | Net income 2025 * | -167M | EV / Sales 2024 * | 4.09 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.53 x |
P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-2.03
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 14.55% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | -0.97% | ||
1 week | -9.73% | ||
Current month | -9.73% | ||
1 month | -10.53% | ||
3 months | -41.71% | ||
6 months | +87.19% | ||
Current year | +28.63% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 1.02 | -0.97% | 1,076,531 |
24-06-06 | 1.03 | -2.83% | 1,829,077 |
24-06-05 | 1.06 | +4.95% | 1,847,593 |
24-06-04 | 1.01 | -5.61% | 4,017,342 |
24-06-03 | 1.07 | -5.31% | 2,229,136 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.63% | 261M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ADAP Stock